Segall Bryant & Hamill LLC Has $23.39 Million Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Segall Bryant & Hamill LLC lowered its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 5.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 149,309 shares of the company’s stock after selling 7,835 shares during the period. Segall Bryant & Hamill LLC’s holdings in Krystal Biotech were worth $23,391,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Krystal Biotech by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company’s stock valued at $450,938,000 after buying an additional 28,707 shares during the period. State Street Corp raised its position in shares of Krystal Biotech by 9.0% in the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after acquiring an additional 119,936 shares during the period. Geode Capital Management LLC boosted its stake in Krystal Biotech by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock worth $107,714,000 after acquiring an additional 11,411 shares during the last quarter. Franklin Resources Inc. grew its holdings in Krystal Biotech by 34.2% during the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after purchasing an additional 62,178 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in Krystal Biotech by 1.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 243,170 shares of the company’s stock valued at $38,095,000 after purchasing an additional 2,954 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

KRYS has been the subject of several research analyst reports. Chardan Capital boosted their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday, February 20th. HC Wainwright restated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Friday, February 28th. Citigroup lifted their price objective on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a report on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. Finally, Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They set a “buy” rating and a $245.00 target price on the stock. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Krystal Biotech currently has a consensus rating of “Buy” and a consensus target price of $220.00.

Insider Activity at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 14.10% of the stock is owned by company insiders.

Krystal Biotech Stock Up 3.9 %

NASDAQ:KRYS opened at $194.44 on Tuesday. The company has a market cap of $5.60 billion, a P/E ratio of 65.03 and a beta of 0.87. Krystal Biotech, Inc. has a twelve month low of $141.72 and a twelve month high of $219.34. The business has a 50 day moving average price of $167.55 and a two-hundred day moving average price of $173.62.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. During the same quarter in the prior year, the company posted $0.30 earnings per share. The firm’s revenue was up 116.4% on a year-over-year basis. As a group, analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).